One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Amryt Pharma plc logo
Amryt Pharma plc AMYT
report update icon

Quarterly report 2021-Q4
added 05-23-2026

Amryt Pharma plc Balance Sheet 2021-2011 | AMYT

Brief overview of Amryt Pharma plc's balance sheet strength

The balance sheet is assessed across five available annual reports spanning 2017 to 2021.

Total assets increased by +749.3%, from $96.1 million to $816.1 million. A CAGR near 70.7% points to substantial expansion.

Growth in the asset base was not matched by liabilities: +749.3% versus +557.9%. The balance sheet moved in a more conservative direction.

Shareholders' equity accounts for 43.7% of assets, previously . Dependence on liabilities is moderate.

Cash exceeds interest-bearing debt, producing net debt of -$107.4 million. The balance sheet therefore carries a net cash position.

Retained earnings remain negative at -$233.3 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.

What the balance sheet shows

Amryt Pharma plc's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.

Annual Balance Sheet Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-107 M -113 M -65.6 M 7.78 M -11.2 M -8.7 M -16.8 M -17.4 M -31.5 M -239 K -1.61 K

Long Term Debt

4.05 M 4.57 M 1.05 M 19 M 12.7 M - - - - - -

Long Term Debt Current

1.54 M 963 K 571 K - - - - - - - -

Total Non Current Liabilities

302 M 369 M 293 M 72.5 M 58.1 M 30.2 M - 79 K 169 K - -

Total Liabilities

459 M 470 M 395 M 84.5 M 69.8 M 33.9 M 504 K 13.2 M 842 K 439 K 43.4 K

Deferred Revenue

- - 23 M - - - - - - - -

Retained Earnings

-233 M -236 M -131 M -69.6 M -42.1 M -9.46 M -44.8 M -5.05 M -2.49 M -3.11 M -3.72 M

Total Assets

816 M 537 M 527 M 80.8 M 96.1 M 68.7 M 17 M 69.2 M 43.7 M 698 K 1.13 M

Cash and Cash Equivalents

113 M 119 M 67.2 M 11.2 M - - - - - - -

Book Value

357 M 66.1 M 132 M -3.7 M 26.3 M 34.7 M 16.5 M 55.9 M 42.8 M 259 K 1.09 M

Total Shareholders Equity

357 M 66.1 M 132 M -3.7 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Amryt Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 4.05 M - - - 4.57 M - - - 1.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 302 M - - - 369 M - - - 293 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 459 M - - - 470 M - - - 395 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -233 M - - - -236 M - - - -131 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 816 M - - - 537 M - - - 527 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 113 M - - - 119 M - - - 67.2 M - - - 11.2 M - - - 24.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 357 M - - - 66.1 M - - - 132 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 357 M - - - 66.1 M - - - 132 M - - - -3.7 M - - - 26 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Amryt Pharma plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Puma Biotechnology Puma Biotechnology
PBYI
$ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.69 -0.67 % $ 281 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
$ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
$ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
$ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
$ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
$ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
$ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
$ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 26.58 -2.37 % $ 4.25 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.06 -10.92 % $ 48.4 M israelIsrael
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
$ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
$ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
$ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
$ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 1.6 -8.86 % $ 13.8 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 112.31 -3.84 % $ 7.3 B usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.29 -2.28 % $ 164 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 32.58 -1.21 % $ 1.87 B usaUSA
Ardelyx Ardelyx
ARDX
$ 2.99 -2.25 % $ 721 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.39 -8.41 % $ 100 M usaUSA
Alector Alector
ALEC
$ 2.34 1.52 % $ 241 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.06 3.43 % $ 56.9 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 21.12 -1.26 % $ 6.62 B usaUSA